



# Tissue-specific cellular immune responses to malaria pre-erythrocytic stages

Olivier Silvie, Rogerio Amino, Julius Clemence Hafalla

## ► To cite this version:

Olivier Silvie, Rogerio Amino, Julius Clemence Hafalla. Tissue-specific cellular immune responses to malaria pre-erythrocytic stages. *Current Opinion in Microbiology*, 2017, 40, pp.160-167. 10.1016/j.mib.2017.12.001 . hal-01700959

**HAL Id: hal-01700959**

**<https://hal.sorbonne-universite.fr/hal-01700959>**

Submitted on 5 Feb 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Tissue-specific cellular immune responses to malaria pre-erythrocytic stages**

Olivier Silvie<sup>1</sup>, Rogerio Amino<sup>2</sup>, Julius Clemence Hafalla<sup>3</sup>

<sup>1</sup> Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, U1135, ERL8255, Paris, France

<sup>2</sup> Unit of Malaria Infection and Immunity, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

<sup>3</sup> Immunology and Infection Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom

Corresponding authors: Silvie, Olivier ([olivier.silvie@inserm.fr](mailto:olivier.silvie@inserm.fr)); Amino, Rogerio ([rogerio.amino@pasteur.fr](mailto:rogerio.amino@pasteur.fr)); Hafalla, Julius ([Julius.Hafalla@lshtm.ac.uk](mailto:Julius.Hafalla@lshtm.ac.uk)).

## **Highlights**

- Protective immunity against malaria can be achieved through immunisation with live attenuated *Plasmodium* sporozoites and targets the parasite pre-erythrocytic stages.
- Naturally exposed individuals remain at risk of malaria despite multiple sporozoite infections, and this could be explained by different mechanisms.
- Protective immunity relies primarily on effector CD8<sup>+</sup> T cells targeting the parasite in the liver.
- The generation of liver-resident parasite-specific memory CD8<sup>+</sup> T cells is emerging as a key determinant of protective immunity.

## Abstract

Complete and long-lasting protective immunity against malaria can be achieved through vaccination with invasive live attenuated *Plasmodium* sporozoites, the motile stage inoculated in the host skin during a mosquito bite. Protective immunity relies primarily on effector CD8<sup>+</sup> T cells targeting the parasite in the liver. Understanding the tissue-specific features of the immune response is emerging as a vital requirement for understanding protective immunity. The small parasite inoculum, the scarcity of infected cells and the tolerogenic properties of the liver represent hurdles for the establishment of protective immunity in endemic areas. In this review, we discuss recent advances on liver-specific features of immunity including innate recognition of malaria pre-erythrocytic stages, CD8<sup>+</sup> T cell interactions with infected hepatocytes, antigen presentation for effective CD8<sup>+</sup> T cell responses and generation of liver-resident memory CD8<sup>+</sup> T cells. A better understanding of the factors involved in the induction and maintenance of effector CD8<sup>+</sup> T cell immunity against malaria pre-erythrocytic stages is crucial for the development of an effective vaccine targeting the initial phase of malaria infection.

## Introduction

Malaria, caused by *Plasmodium* parasites, is one of the leading causes of mortality and morbidity in resource poor areas worldwide. Notwithstanding global control and elimination efforts, >400,000 people still die annually due to malaria (<http://www.who.int/malaria/publications/world-malaria-report-2016/report/en>). A highly efficacious malaria vaccine remains elusive. *Plasmodium* sporozoites are injected in the host skin by a female infected *Anopheles* mosquito. These sporozoites travel to the liver, invade hepatocytes and develop into exo-erythrocytic forms (EEF), which generate thousands of blood stage parasites. Targeting the malaria pre-erythrocytic stage is an ideal and attractive strategy for malaria vaccination. Inhibiting liver infection and development of malaria parasites can prevent both the disease-causing blood stages and the transmissible sexual stages.

Humans, rhesus monkeys and mice exposed to multiple doses of  $\gamma$ -radiation-attenuated sporozoites (RAS), the gold standard vaccine for malaria, can be fully protected against normal sporozoite challenge (reviewed in [1]). Alternative attenuation strategies, such as genetically attenuated parasites (GAP) or chemoprophylaxis with sporozoite infection (CPS), also induce sterile protection (reviewed in [2]). Whilst the use of attenuated parasites is a feasible approach for vaccination, they demand production of large quantities of infected mosquitoes that is not easily scalable to mass vaccination in poor settings. But, if we can discover the important features of a protective immune response, we can replicate these phenotypes by sub-unit vaccination. RTS,S/AS01, the most advanced malaria sub-unit vaccine candidate to date, is based on the circumsporozoite protein (CSP), the surface coat antigen of sporozoites. Yet, despite being designed to elicit different arms of the immune response, RTS,S/AS01 only provides partial protection in malaria-naïve and –experienced individuals [3•].

In rodent models and rhesus monkeys, protection conferred by RAS vaccination is largely dependent on effector CD8<sup>+</sup> T cells (reviewed in [4]). Depletion of CD8<sup>+</sup> T cells prior to challenge of immunised mice and rhesus monkeys consistently abrogated protection [5,6]. *P. falciparum* (*Pf*) RAS vaccination of humans induces high numbers of sporozoite-specific CD8<sup>+</sup> T cells producing IFN- $\gamma$  [7]. Understanding the key features of host-parasite interactions and the induction of innate and adaptive immune responses, particularly parasite-specific CD8<sup>+</sup> T cells, is crucial for informing the development of an effective next generation malaria vaccine.

#### **Immunisation with attenuated parasites versus natural infections: numbers matter**

Despite repeated infections, individuals in endemic areas do not develop sterilising protection and those surviving episodes of childhood malaria remain vulnerable to intermittent infections [8]. Several possibilities, including the small number of parasites naturally transmitted by mosquitoes or the down-regulation of immunity by malaria blood infection, can explain the reasons behind the contrasting outcomes with those experimentally vaccinated with attenuated sporozoites (**Figure 1**).

In mice, only ~20-50 *P. yoelii* (*Py*) or *P. berghei* (*Pb*) sporozoites are inoculated in the host skin during an infective bite and only a small fraction invades and develops inside hepatocytes (reviewed in [9]). CD8<sup>+</sup> T cell responses to CSP and sporozoites following *Py* and *Pf* RAS immunisation, respectively, are dependent on antigen dose so low inoculum equates to poor CD8<sup>+</sup> T cell responses [7,10]. In the *Py* model, CD8<sup>+</sup> T cell responses are not readily increased by repeated immunisation [11,12]. To achieve sterile protection in humans, more than 1,000 *Pf* infective bites (*Pf* RAS) are required [13]; this amount corresponds to almost ten years of exposure to *Pf* in a high malaria transmission area [14] but administered in a much shorter period. Sterile protection can also be achieved by the intravenous inoculation

of ~700,000 *Pf* RAS [7]. To protect humans under CPS, fewer *Pf* infective bites (~40) or cryopreserved sporozoites (~150,000) are needed [15,16•]. For CPS, the host is exposed to both pre-erythrocytic and blood stage (transient parasitemia) antigens, and sterile protection is observed only against a *Pf* sporozoite challenge [17]. Comparable to findings in humans, CPS induces efficient protection against *Pb* sporozoite infection, but not against blood stage challenge. This sterilising protection is abolished after depletion of CD8<sup>+</sup> T cells and is not affected by the lack of mature B cells [18,19]. In contrast, CPS vaccination not only induces high levels of antigen-experienced CD8<sup>+</sup> T cells but also targets blood stages of *Py* and *P. chabaudi* (*Pc*) [18,20–22]. In common, the two species used in these studies cause an acute parasitemia that can be naturally controlled by non-vaccinated hosts, indicating a lower stringency for the immune-control of the blood stage infection in comparison to the *Pb* and *Pf* lethal strains. Late arresting *Py* GAPs have been shown to provide superior protective immunity, suggesting a role of mid/late EEFs antigens in protection, and similar to RAS and CPS, sterile protection is dependent on the immunising dose of attenuated sporozoites [23]. These data suggest that exposure to a broad antigenic repertoire, including antigens shared between EEFs and blood stages, improves protection against the pre-erythrocytic stages. Additionally, the absence or the rapid clearance of infected RBCs by RAS/GAP or CPS vaccination, respectively, might impede the deleterious effect of blood infection on antigen presentation [24], the numbers and functionality of CD8<sup>+</sup> T cells [25] or the expansion of regulatory T cells during a prolonged blood-infection [26•]. Overall, the delivery of high doses of sporozoites seems to be a key requirement for the sterile protection elicited by immunization using live attenuated sporozoites. This high antigenic load is likely associated with overcoming the humoral and cellular effector thresholds necessary to sterilize the sporozoite infection [27,28].

## Early responses to sporozoites and liver stages: innate immunity and hepatic responses

Information on how sporozoites interact with the innate immune system remains limited. *Pb* sporozoites induce the biphasic recruitment of CD11b<sup>+</sup> Ly6C<sup>int</sup> Ly6G<sup>hi</sup> polymorphonuclear neutrophils, CD11b<sup>+</sup> Ly6C<sup>-</sup> Ly6G<sup>-</sup> resident myeloid cells and CD11b<sup>+</sup> Ly6C<sup>hi</sup> Ly6G<sup>-</sup> inflammatory monocytes in the skin inoculation site and the proximal draining lymph node (DLN), evoking a Th1 cytokine profile [29]. Migrating *Pb* sporozoites induce a signalling cascade *in vitro* in primary murine hepatocytes with MyD88-mediated NF-KB activation [30]. Although EEF development is clinically silent, accumulating evidence suggest that, as parasites replicate in the liver, functional innate immune responses are triggered that are dependent on both type I and II IFNs [31•,32•]. The type I IFN signaling pathway is activated in the livers of mice intravenously infected with either *Pb* or *Py*, a process that involves the cytosolic receptor melanoma differentiation-associated protein 5 (Mda5), suggesting sensing of parasite RNA, and requires the mitochondrial antiviral signalling protein (Mavs) and the transcription factors interferon-regulatory factors-3 (Irf3) and Irf7. Type I IFNs bind to Ifnar on hepatocytes and leukocytes, resulting in the subsequent recruitment of leukocytes to the liver at the end of the hepatic infection. Indeed, following the inoculation of *Py* GAP, type I IFN signalling is essential for the recruitment or expansion of CD49b<sup>+</sup>CD3<sup>+</sup> Natural Killer T (NKT) cells, one day after the peak of hepatic parasite release in the blood circulation. These NKT cells reduce liver infection during a subsequent and intertwined secondary *Py* sporozoite infection, presumably via the production of IFN- $\gamma$  [32•]. However, type I IFN signalling does not impact the EEF growth after a primary *Pb* or *Py* sporozoite infection [31•,32•]. Furthermore, earlier reports using *Pb* and *Py* suggest that NKT cells have no role in protection against malaria pre-erythrocytic stages [33,34]. Notably, a type I IFN response of much lower magnitude was observed when lower doses of parasites were transmitted through mosquito bites [31•]. Hence, the significance of this response and its

relevance in humans still remains uncertain, as well as its impact on the acquisition of immunity by vaccination using live attenuated sporozoites. During EEF development, the parasite exploits diverse cellular pathways and several host and immune factors are modulated, including Bcl-2, p53, IL-6, heme oxygenase and the autophagy machinery (reviewed in [35,36] and [37]). The relationships amongst the modulation of host cell factors, the innate immune system and the development of protective CD8<sup>+</sup> T cells against pre-erythrocytic stages remain to be established.

### **Antigen capture and presentation leading to CD8<sup>+</sup> T cell priming**

How parasite antigens are processed and presented for primary activation of antigen-specific CD8<sup>+</sup> T cells is not well understood, but likely depends on the nature and spatio-temporal exposure of parasite-derived antigens. Sporozoites migrate through various cell types during their journey from the skin to the liver. During cell traversal, sporozoites shed antigens in the host cell cytosol, which can be processed and directly presented [38] or captured for cross-presentation by dendritic cells (DCs). After dermal inoculation, a fraction of *Pb* sporozoites actively migrate to the DLN [39], and can prime protective *Py*CSP-specific CD8<sup>+</sup> T cells [40]. Lymph-node resident CD8 $\alpha$ <sup>+</sup> DCs capture antigens from migratory malaria sporozoites and induce *Pb*CSP-specific CD8<sup>+</sup> T cell responses [41]. Intravenous inoculation of live attenuated sporozoites is a more efficient vaccination approach as compared to intradermal inoculation, in both human and rodents models [7,42]. Various factors likely concur to protective immunity induced by immunization with live attenuated sporozoites administered intravenously (**Figure 2**). A recent study revealed that the lower protective efficacy of *Py* GAP administered via the intradermal route is not linked to low hepatic parasite numbers, but correlates with a shift towards regulatory immune responses [43•]. In particular, more interleukin-10-producing B and T cells but fewer hepatic memory CD8<sup>+</sup> T cells and CD8 $\alpha$ <sup>+</sup>



DCs were found in the liver and skin DLNs after intradermal injection, as compared to intravenous inoculation. Intravenous injection of *Pb* RAS leads to a CD8 $\alpha$ <sup>+</sup> DC-dependent splenic priming of CD8<sup>+</sup> T cells specific for an antigen expressed in pre-erythrocytic and blood stages [44]. CD8 $\alpha$ <sup>+</sup> DCs accumulate in the liver after *Pb* RAS immunisation [45,46], however a role for hepatic DCs in both priming of CD8<sup>+</sup> T cells and protection remains poorly characterised. In the liver, sporozoites traverse Kupffer cells (KC) and liver sinusoidal endothelial cells (LSEC) prior to infecting hepatocytes [47]. In other systems, both KC and LSEC can function as APCs and could present parasite antigens to CD8<sup>+</sup> T cells, resulting in either tolerance or enhanced immune responses in inflammatory conditions [48,49].

How antigens expressed exclusively during EEF development are presented to the immune system is unclear. After invasion of hepatocytes, *Plasmodium* parasites replicate within the PV membrane (PVM), which constitutes a barrier preventing access of antigens to the host cell cytosol and the MHC class I presentation pathway. RAS and GAP invade hepatocytes where they undergo arrested development into EEFs. Attenuation leads to parasite death and possible breakdown of the PVM, which could also enhance antigen presentation and priming of protective CD8<sup>+</sup> T cells. Although antigen presentation by hepatocytes tends to have a tolerising effect (reviewed in [50]), hepatocytes were shown to prime CD8<sup>+</sup> T cells specific for CSP [51]. Furthermore, a recent study revealed that presentation of antigens expressed in hepatocytes leads to differentiation of systemically primed CD8<sup>+</sup> T cells into liver-resident memory cells that are critical for protection [52••].

During the effector phase of an efficient immune response, protective CD8<sup>+</sup> T cells recognize parasite-derived peptides displayed with MHC class I molecules on the surface of infected hepatocytes, leading to parasite elimination [40,53,54]. In *Py*-infected hepatocytes, antigen processing and presentation follows an endosomal-independent, TAP-dependent pathway [53,55] requiring an intracellular source of parasite antigens. From thousands of

proteins expressed by sporozoites and liver-stages, so far, only a few antigens, conserved among plasmodial species, are known to elicit a CD8<sup>+</sup> T cell-dependent protection against a sporozoite infection. Among them are the two most abundant surface proteins of sporozoites, CSP [56] and the thrombospondin-related anonymous protein (TRAP/SSP2) [57]; a protein involved in the wounding and traversal of host cells by ookinetes and sporozoites (CelTOS) [58]; an asparagine-rich protein that regulates the initial development of liver stages (SLARP/SAP1) and a putative serine hydroxymethyltransferase (SHMT) [59]. *Pf* liver-stage antigen 1, liver-stage associated protein 2 and UIS3 antigens also elicit CD8<sup>+</sup> T cell-dependent protection in a challenge model where heterologous *Pb* sporozoites over-express these antigens via the strong *uis4* promoter [60,61]. The expression of the OVA MHC-I epitope fused to the HSP70 or the green fluorescent protein in the parasite cytosol via the constitutive *hsp70* promoter can also lead to the elimination of infected hepatocytes by OVA-specific CD8<sup>+</sup> T cells [53], showing that cytosolic, membrane, secreted and PVM antigens can be potentially presented on the surface of infected hepatocytes.

### **Effector functions of protective CD8<sup>+</sup> T cells**

Different effector molecules can be utilised by both effector and memory CD8<sup>+</sup> T cells to protect against infections, including IFN- $\gamma$ , tumour necrosis factor (TNF), perforin, granzyme, FasL and TNF-related apoptosis-inducing ligand (TRAIL). The mechanisms by which CD8<sup>+</sup> T cells inhibit the development of pre-erythrocytic stages remain poorly understood. Studies using antigenically distinct *Pb* strains showed that bystander killing of parasites does not occur during the CD8<sup>+</sup> T cell response to malaria parasites [62], indicating that elimination of infected parasites is likely mediated by direct recognition of infected hepatocytes by antigen-specific CD8<sup>+</sup> T cells. Systemic depletion of IFN- $\gamma$  which is produced not only by CD8<sup>+</sup> T cells but also by CD4<sup>+</sup> T, NK T and NK cells, consistently abolishes

sterile protection in rodent models immunised with *Pb* or *Py* RAS [5]; IFN- $\gamma$  activates the L-arginine-dependent inducible nitric oxide synthase (iNOS) pathway, which leads to the production of nitric oxide (NO) that is toxic to the developing EEFs (reviewed in [1]). Lytic factors appear to be dispensable in the effector function of CD8<sup>+</sup> T cells against pre-erythrocytic stages. Mice deficient for perforin, granzyme B or FasL and immunised with either *Pb* or *Py* RAS are completely protected against sporozoite challenge [5,63]. However, the roles for other immune mechanisms were not properly studied in these gene-deficient animals. Several experiments have also been performed using peptide-stimulated activated CD8<sup>+</sup> T cells or vaccine-induced CD8<sup>+</sup> T cells. Activated CD8<sup>+</sup> T cells specific for a cytoplasmic antigen in EEFs and generated by peptide-stimulation were shown to eliminate developing parasites in the liver in the absence of IFN- $\gamma$  [53]. Effector *Py*CSP-specific CD8<sup>+</sup> T cells that are deficient of perforin, granzyme B or FasL, and generated following vaccination with recombinant vaccinia virus, were capable of targeting the developing EEFs [64]. Finally, an immunisation strategy involving priming with DCs and boosting with recombinant *Listeria monocytogenes* to generate memory *Pb*CSP- or *Py*CSP-specific memory cells showed the importance of both IFN- $\gamma$  and TNF in protection against *Pb* and *Py*, whilst perforin was only involved in protection against *Py*, providing evidence of species-specific effector mechanisms for parasite killing [65].

Live cell imaging was utilised to dissect the fine mechanisms of CD8<sup>+</sup> T cell recognition of infected hepatocytes. Polyclonal CD8<sup>+</sup> T cells from mice immunised with *Py* GAP were shown to establish immunological synapses *in vitro* and utilise perforin to induce massive apoptosis of infected hepatocytes, with no detectable production of IFN- $\gamma$  and TNF [66]. Intravital imaging revealed that *Py*CSP-specific effector CD8<sup>+</sup> T cells (generated by peptide-stimulation or a recombinant viral vaccination), as well as non-specific CD8<sup>+</sup> T cells, form clusters around infected hepatocytes, a process requiring G protein-coupled receptors

[53,67]. Targeting by *Py*CSP-specific effector CD8<sup>+</sup> T cells showed heterogeneity in the death phenotypes of the parasite, implying that multiple and redundant mechanisms are involved [67]. Taken together, these findings uphold the view that elimination of infected hepatocytes occurs in a multifaceted process.

### **The role of liver-resident memory CD8<sup>+</sup> T cells in protective immunity**

To induce sterilising immunity against EEFs, CD8<sup>+</sup> resident or recruited to the liver must locate and eliminate all parasites to prevent progression to the blood stage infection [62], in a limited amount of time (2 days in mouse, 7-10 days in humans). CD8<sup>+</sup> T cells must find rare events: estimated at 1 out of 10<sup>9</sup> hepatocytes in humans and 1 out of 10<sup>6</sup> hepatocytes in mice [4]. Consequently, extremely high numbers of circulating vaccine-induced effector CD8<sup>+</sup> T cells are required to scan, locate and kill infected hepatocytes in the short amount of time the parasites are in the liver [28,68].

Accumulating evidence indicates a vital role for liver-resident CD8<sup>+</sup> T cells in protective immunity to pre-erythrocytic stages. Long-term protection after immunisation with *Pb* RAS and CPS correlates with sustained IFN- $\gamma$  responses of hepatic CD8<sup>+</sup> memory T cells [69]. Recent studies in non-human primates have also correlated liver CD8<sup>+</sup> T cell numbers with protective efficacy after intravenous RAS vaccination [70•]. Memory *Py*CSP-specific CD8<sup>+</sup> T cells express high levels of CXCR6 [71]. Poor CXCR6 expression in these cells results in a reduction of both liver-associated memory and protective immunity [72], suggesting a role of resident CD8<sup>+</sup> T cells in protection. Intravital imaging documented the presence of motile CD8<sup>+</sup> T cells within the liver sinusoids of *Py* RAS vaccinated mice, suggesting that memory T cells survey for liver infection by patrolling the sinusoids [73]. More recently, a study based on transgenic CD8<sup>+</sup> T cells specific for a *Pb* antigen expressed in pre-erythrocytic and blood stages, identified a population of memory CD8<sup>+</sup> T cells in the

liver that express a distinct phenotype (CD69<sup>+</sup> KLRG1<sup>lo</sup>) from splenic memory cells that are CD69<sup>+</sup> KLRG1<sup>hi</sup> [52••]. Detailed phenotypic analysis revealed that liver Trm cells also lacked CD103 expression and differentially expressed a number of surface markers, with higher levels of CXCR3, CXCR6, CD101, BTLA, FR4, Ly6ae, CD25, CD31, CD93, IL-4R, CD127, gp130, CD200R, and CD43, but lower levels of CX3CR1 and NKG2D as compared to circulating effector memory T cells [52••]. Induced following Pb RAS immunisation, these tissue-resident memory T (Trm) cells have the core gene signature of Trm cells from gut, skin and lung. Parabiosis experiments in mice showed that these cells do not recirculate, confirming their liver-resident status [52••]. Intravital imaging revealed that liver-resident cells depend on LFA-ICAM-1 interactions [74]. An immunisation strategy, which involves systemic DC-targeted priming followed by the expression of the antigen on hepatocytes to trap circulating primed CD8<sup>+</sup> T cells in the liver, enabled conversion to Trm cells [52••]. In this study, DC-targeted priming was achieved by conjugating the peptide antigen to a monoclonal antibody that targets the surface receptor Clec9A, which is expressed by CD8α<sup>+</sup> DCs, and a recombinant adeno-associated virus that targets hepatocytes was used to express the antigen in the liver. This prime-trap vaccination strategy was shown to protect against normal *Pb* sporozoite challenge [52••].

## Conclusion

Despite the strong evidence for the role of CD8<sup>+</sup> T cells in sterile protection against malaria, critical qualitative and quantitative characteristics of the protective response and effector mechanisms engaged by CD8<sup>+</sup> T cells have only started to emerge recently. Whilst multiple immune mechanisms appear to contribute to protection against pre-erythrocytic stages, the generation of liver-resident parasite-specific memory CD8<sup>+</sup> T cells is emerging as a key determinant of protective immunity. The design of strategies inducing this type of

response and the identification of protective target antigens will be instrumental for the development of an efficacious malaria vaccine.

## **Acknowledgements**

OS is supported by grants from the European Union (FP7 PathCo Collaborative Project HEALTH-F3-2012-305578), the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "ParaFrap" (ANR-11-LABX-0024), and the French National Research Agency (MALINV project, ANR-16-CE15-0004-01). RA is supported by grants from the Institut Pasteur – Paris, the French National Research Agency (ANR-14-CE16-Im3alaria) and the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (ANR-10-LABX-62-IBEID). JCH is supported by university research fellowships (UF0762736 and UF120026) and grants (RG130034, IE131078, IE14111 and CH160018) from the Royal Society (United Kingdom), as well as a project grant (NC/L000601/1) from the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs).

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

• of special interest

•• of outstanding interest

1. Hafalla JC, Silvie O, Matuschewski K: **Cell biology and immunology of malaria.** *Immunol Rev* 2011, **240**:297–316.

2. Bijker EM, Borrmann S, Kappe SH, Mordmüller B, Sack BK, Khan SM: **Novel approaches to whole sporozoite vaccination against malaria.** *Vaccine* 2015, **33**:7462–7468.

3. • RTSS Clinical Trials Partnership: **Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.** *Lancet* 2015, **386**:31–45.

Final report on the efficacy and safety of the RTS,S/AS01 malaria vaccine candidate, in a phase 3 trial involving more than 15000 children. Describes its overall efficacy and its decreased efficacy with time.

4. Van Braeckel-Budimir N, Harty JT: **CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model.** *Front Microbiol* 2014, **5**:272.

5. Doolan DL, Hoffman SL: **The Complexity of Protective Immunity Against Liver-Stage Malaria.** *J Immunol* 2000, **165**:1453–1462.

6. Weiss WR, Jiang CG: **Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites.** *PLoS One* 2012, **7**:e31247.

7. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, et al.: **Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.** *Science* 2013,

336        **341:1359–1365.**

337    8.    Tran TM, Li S, Doumbo S, Doumtabe D, Huang C-Y, Dia S, Bathily A, Sangala J,  
338        Kone Y, Traore A, et al.: **An Intensive Longitudinal Cohort Study of Malian**  
339        **Children and Adults Reveals No Evidence of Acquired Immunity to Plasmodium**  
340        **falciparum Infection.** *Clin Infect Dis* 2013, **57**:40–47.

341    9.    Vanderberg JP: **Imaging mosquito transmission of Plasmodium sporozoites into the**  
342        **mammalian host: Immunological implications.** *Parasitol Int* 2014, **63**:150–164.

343    10.    Hafalla JCR, Sano G -i., Carvalho LH, Morrot A, Zavala F: **Short-term antigen**  
344        **presentation and single clonal burst limit the magnitude of the CD8+ T cell**  
345        **responses to malaria liver stages.** *Proc Natl Acad Sci* 2002, **99**:11819–11824.

346    11.    Hafalla JC, Morrot A, Sano G, Milon G, Lafaille JJ, Zavala F: **Early self-regulatory**  
347        **mechanisms control the magnitude of CD8+ T cell responses against liver stages**  
348        **of murine malaria.** *J Immunol* 2003, **171**:964–970.

349    12.    Cockburn I a, Chakravarty S, Overstreet MG, García-Sastre A, Zavala F, Garcia-Sastre  
350        A, Zavala F: **Memory CD8+ T cell responses expand when antigen presentation**  
351        **overcomes T cell self-regulation.** *J Immunol* 2008, **180**:64–71.

352    13.    Hoffman SL, Goh LML, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega  
353        P, Dowler M, Paul C, et al.: **Protection of humans against malaria by immunization**  
354        **with radiation-attenuated Plasmodium falciparum sporozoites.** *J Infect Dis* 2002,  
355        **185**:1155–64.

356    14.    Kilama M, Smith DL, Hutchinson R, Kigozi R, Yeka A, Lavoy G, Kamya MR,  
357        Staedke SG, Donnelly MJ, Drakeley C, et al.: **Estimating the annual entomological**  
358        **inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae**  
359        **s.l. using three sampling methods in three sites in Uganda.** *Malar J* 2014, **13**:111.

360    15.    Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de



- 361 Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, et al.: **Protection against a**  
 362 **malaria challenge by sporozoite inoculation.** *N Engl J Med* 2009, **361**:468–477.
- 363 16. • Mordmüller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A,  
 364 Gmeiner M, Campo JJ, Esen M, Ruben AJ, et al.: **Sterile protection against human**  
 365 **malaria by chemoattenuated PfSPZ vaccine.** *Nature* 2017, **542**:445–449.
- 366 Reports high-level protection against homologous challenge in malaria-naïve volunteers  
 367 vaccinated with purified cryopreserved PfSPZ administered intravenously under  
 368 chemoprophylaxis.
- 369 17. Bijker EM, Bastiaens GJH, Teirlinck AC, van Gemert G-J, Graumans W, van de  
 370 Vegte-Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W, et al.:  
 371 **Protection against malaria after immunization by chloroquine prophylaxis and**  
 372 **sporozoites is mediated by preerythrocytic immunity.** *Proc Natl Acad Sci U S A*  
 373 2013, **110**:7862–7.
- 374 18. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, Leroy N, Rodrigues MM,  
 375 Landau I, Snounou G, Renia L: **Protective T cell immunity against malaria liver**  
 376 **stage after vaccination with live sporozoites under chloroquine treatment.** *J*  
 377 *Immunol* 2004, **172**:2487–2495.
- 378 19. Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, Borrmann S: **Natural**  
 379 **immunization against malaria: causal prophylaxis with antibiotics.** *Sci Transl Med*  
 380 2010, **2**:40ra49.
- 381 20. Doll KL, Butler NS, Harty JT: **CD8 T cell independent immunity after single dose**  
 382 **infection-treatment-vaccination (ITV) against Plasmodium yoelii.** *Vaccine* 2014,  
 383 **32**:483–491.
- 384 21. Nahrendorf W, Spence PJ, Tumwine I, Lévy P, Jarra W, Sauerwein RW, Langhorne J:  
 385 **Blood-stage immunity to Plasmodium chabaudi malaria following**

**chemoprophylaxis and sporozoite immunization. *Elife* 2015, 2015.**

22. Peng X, Keitany GJ, Vignali M, Chen L, Gibson C, Choi K, Huang F, Wang R: **Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic *Plasmodium yoelii* infection. *J Immunol* 2014, 193:1268–77.**

23. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SHI, Harty JT: **Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. *Cell Host Microbe* 2011, 9:451–462.**

24. Ocana-Morgner C, Mota MM, Rodriguez a.: **Malaria Blood Stage Suppression of Liver Stage Immunity by Dendritic Cells. *J Exp Med* 2003, 197:143–151.**

25. Horne-Debets JM, Faleiro R, Karunaratne DS, Liu XQ, Lineburg KE, Poh CM, Grotenbreg GM, Hill GR, MacDonald KPA, Good MF, et al.: **PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. *Cell Rep* 2013, 5:1204–1213.**

26. • Kurup SP, Obeng-Adjei N, Anthony SM, Traore B, Doumbo OK, Butler NS, Crompton PD, Harty JT: **Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. *Nat Med* 2017, doi:10.1038/nm.4395.**

Describes a critical mechanism of immunosuppression associated with blood-stage malaria that delays parasite clearance and prevents development of potent adaptive immunity to reinfection in mice.

27. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC: **The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against *Plasmodium falciparum* infection. *PLoS One* 2013, 8:e61395.**

28. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS,

Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, et al.: **Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria.** *Proc Natl Acad Sci U S A* 2008, **105**:14017–22.

29. Mac-Daniel L, Buckwalter MR, Berthet M, Virk Y, Yui K, Albert ML, Gueirard P, Menard R: **Local Immune Response to Injection of Plasmodium Sporozoites into the Skin.** *J Immunol* 2014, **193**:1246–1257.

30. Torgler R, Bongfen SE, Romero JC, Tardivel A, Thome M, Corradin G: **Sporozoite-mediated hepatocyte wounding limits Plasmodium parasite development via MyD88-mediated NF-kappa B activation and inducible NO synthase expression.** *J Immunol* 2008, **180**:3990–3999.

31. • Liehl P, Zuzarte-Luís V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassnig C, et al.: **Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection.** *Nat Med* 2014, **20**:47–53.

Reports innate immune sensing of malaria parasite liver-stage infection with a type I interferon response during *Plasmodium* replication in the liver.

32. • Miller JL, Sack BK, Baldwin M, Vaughan AM, Kappe SHI: **Interferon-Mediated Innate Immune Responses against Malaria Parasite Liver Stages.** *Cell Rep* 2014, **7**:436–447.

Reports innate immune sensing of malaria parasite liver-stage infection with a type I interferon response during *Plasmodium* replication in the liver.

33. Romero JF, Eberl G, MacDonald HR, Corradin G: **CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice.** *Parasite Immunol* 2001, **23**:267–269.

34. Soulard V, Roland J, Sellier C, Gruner AC, Leite-de-Moraes M, Franetich JF, Renia L, Cazenave PA, Pied S: **Primary infection of C57BL/6 mice with Plasmodium yoelii**

induces a heterogeneous response of NKT cells. *Infect Immun* 2007, **75**:2511–2522.

35. Kaushansky A, Kappe SHI: **Selection and refinement: The malaria parasite's infection and exploitation of host hepatocytes.** *Curr Opin Microbiol* 2015, **26**:71–78.

36. Coppens I: **How Toxoplasma and malaria parasites defy first, then exploit host autophagic and endocytic pathways for growth.** *Curr Opin Microbiol* 2017, **40**:32–39.

37. Mathieu C, Demarta-Gatsi C, Porcherie A, Brega S, Thiberge S, Ronce K, Smith L, Peronet R, Amino R, Ménard R, et al.: **Plasmodium berghei histamine-releasing factor favours liver-stage development via inhibition of IL-6 production and associates with a severe outcome of disease.** *Cell Microbiol* 2015, **17**:542–558.

38. Bongfen SE, Torgler R, Romero JF, Renia L, Corradin G: **Plasmodium berghei-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro.** *J Immunol* 2007, **178**:7054–7063.

39. Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, Ménard R: **Quantitative imaging of Plasmodium transmission from mosquito to mammal.** *Nat Med* 2006, **12**:220–224.

40. Chakravarty S, Cockburn IA, Kuk S, Overstreet MG, Sacci JB, Zavala F: **CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes.** *Nat Med* 2007, **13**:1035–1041.

41. Radtke AJ, Kastenmüller W, Espinosa DA, Gerner MY, Tse S-W, Sinnis P, Germain RN, Zavala FP, Cockburn IA: **Lymph-Node Resident CD8α+ Dendritic Cells Capture Antigens from Migratory Malaria Sporozoites and Induce CD8+ T Cell Responses.** *PLOS Pathog* 2015, **11**:e1004637.

42. Epstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, et al.: **Live Attenuated Malaria Vaccine**

**Designed to Protect Through Hepatic CD8+ T Cell Immunity.** *Science* 2011, **334**:475–480.

43. • Haeblerlein S, Chevalley-Maurel S, Ozir-Fazalalikhan A, Koppejan H, Winkel BMF, Ramesar J, Khan SM, Sauerwein RW, Roestenberg M, Janse CJ, et al.: **Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load.** *Sci Rep* 2017, **7**:10372.

Reports that intravenous administration of attenuated malaria sporozoites provides better protective efficacy compared to the intradermal route, independent of parasite liver load.

44. Lau LS, Fernandez-Ruiz D, Mollard V, Sturm A, Neller MA, Cozijnsen A, Gregory JL, Davey GM, Jones CM, Lin YH, et al.: **CD8+ T Cells from a Novel T Cell Receptor Transgenic Mouse Induce Liver-Stage Immunity That Can Be Boosted by Blood-Stage Infection in Rodent Malaria.** *PLoS Pathog* 2014, **10**.

45. Jobe O, Donofrio G, Sun G, Liepnish D, Schwenk R, Krzych U: **Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8 $\alpha$ +DC that activate CD8+T cells against liver-stage malaria.** *PLoS One* 2009, **4**.

46. Montagna GN, Biswas A, Hildner K, Matuschewski K, Dunay IR: **Batf3 deficiency proves the pivotal role of CD8 $\alpha$ (+) dendritic cells in protection induced by vaccination with attenuated Plasmodium sporozoites.** *Parasite Immunol* 2015, **37**:533–543.

47. Tavares J, Formaglio P, Thiberge S, Mordet E, Van Rooijen N, Medvinsky A, Ménard R, Amino R: **Role of host cell traversal by the malaria sporozoite during liver infection.** *J Exp Med* 2013, **210**:905–15.

48. Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P, Martin C, van Rooijen N, Ochando JC, Randolph GJ, et al.: **Liver Inflammation Abrogates Immunological Tolerance Induced by Kupffer Cells.** *Hepatology* 2015,

486 62:279–291.

- 487 49. Crispe IN, Giannandrea M, Klein I, John B, Sampson B, Wuensch S: **Cellular and**  
488 **molecular mechanisms of liver tolerance.** *Immunol Rev* 2006, **213**:101–118.
- 489 50. Bertolino P, Bowen DG: **Malaria and the liver: Immunological hide-and-seek or**  
490 **subversion of immunity from within?** *Front Microbiol* 2015, **6**:41.
- 491 51. Balam S, Romero JF, Bongfen SE, Guillaume P, Corradin G: **CSP-A Model for In**  
492 **Vivo Presentation of Plasmodium berghei Sporozoite Antigens by Hepatocytes.**  
493 *PLoS One* 2012, **7**:e51875.
- 494 52. •• Fernandez-Ruiz D, Ng WY, Holz LE, Ma JZ, Zaid A, Wong YC, Lau LS, Mollard V,  
495 Cozijnsen A, Collins N, et al.: **Liver-Resident Memory CD8+ T Cells Form a Front-**  
496 **Line Defense against Malaria Liver-Stage Infection.** *Immunity* 2016, **45**:889–902.  
497 Identifies a population of tissue-resident memory (Trm) CD8+ T cells associated with  
498 protection against malaria sporozoite challenge in mice, and reports a vaccination strategy to  
499 induce high frequencies of Trm cells.
- 500 53. Kimura K, Kimura D, Matsushima Y, Miyakoda M, Honma K, Yuda M, Yuia K:  
501 **CD8+ T cells specific for a malaria cytoplasmic antigen form clusters around**  
502 **infected hepatocytes and are protective at the liver stage of infection.** *Infect Immun*  
503 2013, **81**:3825–3834.
- 504 54. Huang J, Tsao T, Zhang M, Rai U, Tsuji M, Li X: **A sufficient role of MHC class I**  
505 **molecules on hepatocytes in anti-plasmodial activity of CD8+ T cells in vivo.** *Front*  
506 *Microbiol* 2015, **6**:69.
- 507 55. Cockburn IA, Tse SW, Radtke AJ, Srinivasan P, Chen YC, Sinnis P, Zavala F:  
508 **Dendritic cells and hepatocytes use distinct pathways to process protective antigen**  
509 **from Plasmodium in vivo.** *PLoS Pathog* 2011, **7**:e1001318.
- 510 56. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F:

**Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria.** *Nature* 1989, **341**:323–326.

57. Hafalla JCR, Bauza K, Friesen J, Gonzalez-Aseguinolaza G, Hill AVS, Matuschewski K: **Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling.** *PLoS Pathog* 2013, **9**.

58. Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E: **Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.** *Vaccine* 2011, **29**:5940–5949.

59. Speake C, Pichugin A, Sahu T, Malkov V, Morrison R, Pei Y, Juompan L, Milman N, Zarling S, Anderson C, et al.: **Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.** *PLoS One* 2016, **11**:e0159449.

60. Longley RJ, Salman AM, Cottingham MG, Ewer K, Janse CJ, Khan SM, Spencer AJ, Hill AVS: **Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.** *Sci Rep* 2015, **5**:11820.

61. Longley RJ, Halbroth BR, Salman AM, Ewer KJ, Hodgson SH, Janse CJ, Khan SM, Hill AVS, Spencer AJ: **Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.** *Infect Immun* 2017, **85**:e00641-16.

62. Cockburn IA, Tse SW, Zavala F: **CD8+ T cells eliminate liver-stage Plasmodium berghei parasites without detectable bystander effect.** *Infect Immun* 2014, **82**:1460–1464.

63. Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, Corradin G: **Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated**

536 **cytotoxicity**. *Parasite Immunol* 1997, **19**:145–148.

537 64. Morrot A, Zavala F: **Effector and memory CD8+ T cells as seen in immunity to**  
538 **malaria**. *Immunol Rev* 2004, **201**:291–303.

539 65. Butler NS, Schmidt NW, Harty JT: **Differential effector pathways regulate memory**  
540 **CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites**. *J*  
541 *Immunol* 2010, **184**:2528–2538.

542 66. Trimnell A, Takagi A, Gupta M, Richie TL, Kappe SH, Wang R: **Genetically**  
543 **attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of**  
544 **Plasmodium yoelii liver stage-infected hepatocytes**. *J Immunol* 2009, **183**:5870–  
545 5878.

546 67. Cockburn IA, Amino R, Kelemen RK, Kuo SC, Tse S-W, Radtke A, Mac-Daniel L,  
547 Ganusov V V., Zavala F, Menard R: **In vivo imaging of CD8+ T cell-mediated**  
548 **elimination of malaria liver stages**. *Proc Natl Acad Sci* 2013, **110**:9090–9095.

549 68. Patel H, Yadav N, Parmar R, Patel S, Singh AP, Shrivastava N, Dalai SK: **Frequent**  
550 **inoculations with radiation attenuated sporozoite is essential for inducing sterile**  
551 **protection that correlates with a threshold level of Plasmodia liver-stage specific**  
552 **CD8 + T cells**. *Cell Immunol* 2017, **317**:48–54.

553 69. Nganou-makamdop K, Gemert G Van, Arens T, Hermesen CC, Sauerwein RW: **Long**  
554 **Term Protection after Immunization with P . berghei Sporozoites Correlates with**  
555 **Sustained IFN c Responses of Hepatic CD8 + Memory T Cells**. 2012, **7**:1–9.

556 70. • Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME,  
557 Gordon IJ, Chang L-J, Sarwar UN, et al.: **Protection against malaria at 1 year and**  
558 **immune correlates following PfSPZ vaccination**. *Nat Med* 2016, **22**:614–623.

559 Reports high frequencies of *P. falciparum*-specific interferon- $\gamma$ -producing CD8<sup>+</sup> T cells in the  
560 liver of nonhuman primates immunised with PfSPZ vaccine administered intravenously.




- 561 71. Tse S-W, Cockburn I a, Zhang H, Scott a L, Zavala F: **Unique transcriptional profile**  
562 **of liver-resident memory CD8+ T cells induced by immunization with malaria**  
563 **sporozoites.** *Genes Immun* 2013, **14**:302–9.
- 564 72. Tse S-W, Radtke AJ, Espinosa DA, Cockburn IA, Zavala F: **The Chemokine**  
565 **Receptor CXCR6 Is Required for the Maintenance of Liver Memory CD8+ T**  
566 **Cells Specific for Infectious Pathogens.** *J Infect Dis* 2014, **210**:1508–1516.
- 567 73. Cabrera M, Pewe LL, Harty JT, Frevert U: **In vivo CD8+ T Cell Dynamics in the**  
568 **Liver of Plasmodium yoelii Immunized and Infected Mice.** *PLoS One* 2013, **8**.
- 569 74. McNamara HA, Cai Y, Wagle M V., Sontani Y, Roots CM, Miosge LA, O'Connor JH,  
570 Sutton HJ, Ganusov V V., Heath WR, et al.: **Up-regulation of LFA-1 allows liver-**  
571 **resident memory T cells to patrol and remain in the hepatic sinusoids.** *Sci Immunol*  
572 2017, **2**:eaaj1996.

## Figure legends

**Figure 1. Potential factors contributing to the lack of protective immunity during natural *Plasmodium* infection.** Under natural transmission conditions, only a few sporozoites are injected by an infected mosquito into the host skin. The motile sporozoites enter the blood stream by traversing a dermal capillary, are transported to the liver and traverse across liver sinusoidal endothelial cells (LSEC) or Kupffer cells (KC) to reach hepatocytes. Sporozoites invade hepatocytes inside a vacuole, where they replicate into thousands of merozoites, which once released into the bloodstream invade erythrocytes and initiate the blood stage infection. A combination of factors concurs to the lack of protective immunity in naturally exposed individuals. Infected mosquitoes inject very low numbers of sporozoites (1). Dermal inoculation is associated with immune regulatory mechanisms (2). The liver environment is prone to immune tolerance (3). The membrane of the parasitophorous vacuole limits diffusion of parasite liver stage antigens and exposure to the immune system (4). The blood stage infection that follows complete parasite development in the liver has immunosuppressive effects on liver stage immunity (5).


**Figure 2. Potential factors contributing to protective immunity against liver stages after immunisation with live attenuated sporozoites administered intravenously.** Immunisation with live attenuated sporozoites administered intravenously is the most efficient approach to confer full protection against normal sporozoite challenge. Under these conditions, high numbers of sporozoites can be inoculated (1), allowing systemic delivery of antigens (2). Alteration of the parasitophorous vacuole integrity in arrested liver stage parasites likely favours exposure of liver stage antigens to the immune system (3). Sporozoite and liver stage antigens can be captured and presented by CD8 $\alpha$ <sup>+</sup> DCs in the spleen and/or the liver draining lymph nodes (DLN) for priming of naïve CD8<sup>+</sup> T cells (4). Exposure of parasite antigens in

the liver leads to the differentiation of activated CD8<sup>+</sup> T cells into tissue-resident memory T (Trm) cells that patrol the liver sinusoids (5). Aborted liver stage development prevents the appearance of an immunosuppressive blood stage infection (6). Upon reinfection or challenge, effector CD8<sup>+</sup> T cells form clusters around infected hepatocytes and can eliminate parasites through direct killing of the infected cell and/or through the release of cytokines that inhibit parasite development (7).



### Factors contributing to protective immunity:

1. High parasite inoculum
2. Systemic delivery of parasite antigens
3. Enhanced access to EEF antigens
4. CD8 $^{+}$  T cell priming by CD8 $\alpha$  DCs
5. Induction of Trm cells
6. Lack of immunosuppressive blood stages
7. CD8 $^{+}$  T cell effector functions:
  - direct killing of infected cells
  - parasite inhibition through cytokine secretion



### Lack of protective immunity:

1. Low parasite inoculum
2. Regulatory mechanisms induced in the skin
3. Immune tolerance in the liver
4. Limited access to EEF antigens
5. Regulatory mechanisms induced by blood stage infection